MedTrace Logo

Efficacy and Tolerability of Erenumab in Patients With Trigeminal Neuralgia

NCT04054024 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 80

Last updated 2019-11-20

No results posted yet for this study

Summary

A placebo-controlled, double-blind, randomized proof-of-concept study to evaluate the efficacy and tolerability of the CGRP receptor antibody erenumab in treating pain experienced by subjects with TN.

Conditions

  • Trigeminal Neuralgia

Interventions

DRUG

Erenumab

140 mg Erenumab

DRUG

Placebos

Saline

Sponsors & Collaborators

  • Danish Headache Center

    lead OTHER

Principal Investigators

  • Lars Bendtsen, MD, Dr Med Sci · Danish Headache Center

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2019-10-28
Primary Completion
2021-10-31
Completion
2021-10-01
FDA Drug
Yes

Countries

  • Denmark

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04054024 on ClinicalTrials.gov